Meds & supplements › Mavacamten
Medicine · Cardiac Myosin Inhibitor
CAMZYOS ® is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.
Selected manufacturer label information, organised into consistent sections by Sofidex. Read the full label at DailyMed ↗
WARNING: RISK OF HEART FAILURE CAMZYOS reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction. Echocardiogram assessments of LVEF are required prior to and during treatment with CAMZYOS. Initiation of CAMZYOS in patients with LVEF <55% is not recommended. Interrupt CAMZYOS if LVEF is <50% at any visit or if the patient experiences heart failure symptoms or worsening clinical status. Concomitant use of CAMZYOS with certain cytochrome P450 inhibitors or discontinuation of certain cytochrome P450 inducers may increase the risk of heart failure due to systolic dysfunction; therefore, the use of CAMZYOS is contraindicated with the following: • Strong CYP2C19 inhibitors • Moderate to strong CYP2C19 inducers or moderate to strong CYP3A4 inducers Because of the risk of heart failure due to systolic dysfunction, CAMZYOS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called CAMZYOS REMS PROGRAM. WARNING: RISK OF HEART FAILURE See full prescribing information for complete boxed warning. • CAMZYOS can cause heart failure due to systolic dysfunction. • Echocardiogram assessments of left ventricular ejection fraction (LVEF) required before and during CAMZYOS use. • Initiation in patients with LVEF <55% not recommended. Interrupt if LVEF <50% or if worsening clinical status. • Certain CYP450 inhibitors and inducers are contraindicated in patients taking CAMZYOS because of an increased risk of heart failure. • CAMZYOS is available only through a restricted program called the CAMZYOS REMS Program.
CAMZYOS ® is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms. CAMZYOS is a cardiac myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.
CAMZYOS may cause serious side effects, including: Heart failure, a condition where the heart cannot pump with enough force. Heart failure is a serious condition that can lead to death. You must have echocardiograms before you take your first dose and during your treatment with CAMZYOS to help your healthcare provider understand how your heart is responding to CAMZYOS.
People who develop a serious infection or irregular heartbeat have a greater risk of heart failure during treatment with CAMZYOS. Tell your healthcare provider or get medical help right away if you develop new or worsening: o shortness of breath o swelling in your legs o chest pain o a racing sensation in your heart (palpitations) o fatigue o rapid weight gain The risk of heart failure is also increased when CAMZYOS is taken with certain other medicines.
Tell your healthcare provider about the medicines you take, both prescribed and obtained over-the-counter, before and during treatment with CAMZYOS. Because of the serious risk of heart failure, CAMZYOS is only available through a restricted program called the CAMZYOS Risk Evaluation and Mitigation Strategy (REMS) Program.
o Your healthcare provider must be enrolled in the CAMZYOS REMS Program in order for you to be prescribed CAMZYOS. o Before you take CAMZYOS, you must enroll in the CAMZYOS REMS Program. Talk to your healthcare provider about how to enroll in the CAMZYOS REMS Program. You will be given information about the program when you enroll.
o Before you take CAMZYOS, your healthcare provider and pharmacist will make sure you understand how to take CAMZYOS safely, which will include returning for echocardiograms when advised by your healthcare provider. CAMZYOS can only be dispensed by a certified pharmacy that participates in the CAMZYOS REMS Program. Your healthcare provider can give you information on how to find a certified pharmacy.
You will not be able to get CAMZYOS at a local pharmacy. o If you have questions about the CAMZYOS REMS Program, ask your healthcare provider, go to www.CAMZYOSREMS.com, or call 1-833-628-7367. See “
Take CAMZYOS exactly as your healthcare provider tells you to take it. Do not change your dose of CAMZYOS without talking to your healthcare provider first. Take CAMZYOS 1 time a day. Swallow the capsule whole. Do not break, open, or chew the capsule. If you miss a dose of CAMZYOS, take it as soon as possible and take your next dose at your regularly scheduled time the next day.
” for information about side effects. What is CAMZYOS? CAMZYOS is a prescription medicine used to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). CAMZYOS may improve your symptoms and your ability to be active. It is not known if CAMZYOS is safe and effective in children. Before taking CAMZYOS, tell your healthcare provider about all of your medical conditions, including if you: are pregnant or plan to become pregnant.
CAMZYOS may harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with CAMZYOS. You may also report your pregnancy by calling Bristol-Myers Squibb at 1-800-721-5072 or www.bms.com. If you are a female and able to become pregnant: o Your healthcare provider will do a pregnancy test before you start treatment with CAMZYOS.
o You should use effective birth control (contraception) during treatment with CAMZYOS and for 4 months after your last dose of CAMZYOS. o CAMZYOS may reduce how well some hormonal birth control works. Talk to your healthcare provider about the use of effective forms of birth control during treatment with CAMZYOS. are breastfeeding or plan to breastfeed.
It is not known if CAMZYOS passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with CAMZYOS. Before and during CAMZYOS treatment, tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Taking CAMZYOS with certain medicines or grapefruit juice may cause heart failure. Do not stop or change the dose of a medicine or start a new medicine without telling your healthcare provider. Especially tell your healthcare provider if you: Take over-the-counter medicines such as omeprazole (for example, Prilosec), esomeprazole (for example, Nexium), or cimetidine (for example, Tagamet).
Take other medicines to treat your obstructive HCM disease. Develop an infection.
Do not take 2 doses on the same day to make up for a missed dose. Your healthcare provider may change your dose, temporarily stop, or permanently stop your treatment with CAMZYOS if you have certain side effects. If you take too much CAMZYOS, call your healthcare provider or go to the nearest hospital emergency room right away.
What are the possible side effects of CAMZYOS? CAMZYOS may cause serious side effects, including: Heart failure. The most common side effects of CAMZYOS include: dizziness and fainting (syncope). These are not all of the possible side effects of CAMZYOS. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
You may also report side effects to Bristol-Myers Squibb at 1-800-721-5072.
Store CAMZYOS at room temperature between 68°F to 77°F (20°C to 25°C). Keep CAMZYOS and all medicines out of the reach of children.
sofidex [Internet]. Daloreum; c2026. Mavacamten; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/mavacamten
sofidex. (2026, August 2). Mavacamten. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/mavacamten
Mavacamten. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/mavacamten
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.